Palvella Therapeutics (PVLA) Net Income Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 60.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 19.97% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 47.10% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -1.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.33% |
| Sep 30, 2025 | 1.65% |
| Jun 30, 2025 | 8.09% |
| Mar 31, 2025 | -3.14% |
| Dec 31, 2024 | 47.75% |
| Sep 30, 2024 | 29.10% |
| Jun 30, 2024 | 37.09% |
| Mar 31, 2024 | 20.55% |
| Dec 31, 2023 | 45.48% |
| Sep 30, 2023 | 4.55% |
| Jun 30, 2023 | 36.87% |
| Mar 31, 2023 | -62.42% |
| Sep 30, 2022 | -66.33% |
| Jun 30, 2022 | -1.23% |
| Mar 31, 2022 | 10.33% |
| Dec 31, 2021 | 1.97% |
| Sep 30, 2021 | -45.64% |
| Jun 30, 2021 | -335.42% |
| Mar 31, 2021 | 16.59% |
| Dec 31, 2020 | -54.05% |
| Sep 30, 2020 | -22.40% |
| Jun 30, 2020 | 23.44% |
| Mar 31, 2020 | 23.80% |
| Dec 31, 2019 | 50.60% |
| Sep 30, 2019 | 25.21% |
| Jun 30, 2019 | -25.96% |
| Mar 31, 2019 | -35.48% |
| Dec 31, 2018 | -59.08% |
| Sep 30, 2018 | -16.19% |
| Jun 30, 2018 | 61.40% |
| Mar 31, 2018 | -32.99% |
| Sep 30, 2017 | -51.70% |
| Jun 30, 2017 | -51.83% |
| Mar 31, 2017 | -117.22% |
| Dec 31, 2016 | -1,327.70% |
| Sep 30, 2016 | -924.51% |
| Jun 30, 2016 | -2,679.43% |